search icon

      Market Snapshot

      blog search icon

      Lipocine Stock Price History and Quote Analysis: Insights for Investors

      Lipocine Inc.

      (NASDAQ:LPCN)

      $4.66

      -0.71 (-13.22%)

      At Close: 4:00 PM

      $5.14

      -0.23 (-4.28%)

      Pre Market: 7:03 AM

      Lipocine Stock Price Graph

      • 1D
      • 5D
      • 1M
      • 3M
      • 6M
      • 1Y
      • YTD
      • All

      Lipocine Stock Price Today

      Lipocine Inc. (LPCN) stock declined over -13.22% intraday to trade at $4.66 a share on NASDAQ. The stock opened with a loss of -0.93% at $5.32 and touched an intraday high of $5.47, falling -13.22% against the last close of $5.37. The Lipocine Inc. in stock market went to a low of $4.91 during the session.

      Lipocine Stock Snapshot

      $5.37

      Prev. Close

      20.65 Million

      Market Cap

      $4.91

      Day Low

      $5.32

      Open

      90.19 Million

      Number of Shares

      $5.47

      Day High

      N/A

      P/E ratio

      -0.12

      EPS (TTM)

      5.55

      Cash Flow per Share

      0.00

      Free Float in %

      6.14

      Book Value

      15435.00

      Volume

      Lipocine Stock Price History Chart

      DateOpenHighLowCloseVolume
      2023-02-14$0.53$0.54$0.51$0.53102965.00
      2023-02-13$0.53$0.56$0.52$0.5462200.00
      2023-02-10$0.54$0.56$0.52$0.53107000.00
      2023-02-08$0.55$0.55$0.54$0.5482755.00
      2023-02-07$0.53$0.56$0.53$0.5558500.00
      2023-02-06$0.55$0.56$0.54$0.54119700.00
      2023-02-03$0.55$0.56$0.53$0.55133279.00
      2023-02-02$0.52$0.56$0.52$0.55266300.00
      2023-02-01$0.51$0.54$0.51$0.5257300.00
      2023-01-31$0.51$0.54$0.51$0.5363400.00

      Contact Details

      675 Arapeen Drive
      Salt Lake City, UT 84108
      US

      Website:https://www.lipocine.com

      Contact #:801 994 7383

      Company Information

      Employees17.00

      Beta0.94

      Sales or Revenue$554.99 Thousands

      5Y Sales ChangeN/A

      Fiscal Year EndsDec. 2022

      SectorHealthcare

      IndustryBiotechnology

      About Company

      Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

      Frequently Asked Questions

      icon

      What is the current Lipocine Inc. (LPCN) stock price?

      Lipocine Inc. (NASDAQ: LPCN) stock price is $4.66 in the last trading session. During the trading session, LPCN stock reached the peak price of $5.47 while $4.91 was the lowest point it dropped to. The percentage change in LPCN stock occurred in the recent session was -13.22% while the dollar amount for the price change in LPCN stock was -$0.71.

      icon

      LPCN's industry and sector of operation?

      The NASDAQ listed LPCN is part of Biotechnology industry that operates in the broader Healthcare sector. Lipocine Inc. , a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders.

      icon

      Who are the executives of LPCN?

      Ms. Krista Fogarty
      Principal Accounting Officer & Corporation Controller
      Dr. Mahesh V. Patel Ph.D.
      Co-Founder, Interim Principal Financial Officer, Director, Pres & Chief Executive Officer
      Mr. Logan Morse
      Vice President of Sales, Marketing & Operations
      Mr. Morgan R. Brown CPA, CPA, M.B.A., MBA
      Corporation Sec.

      icon

      How LPCN did perform over past 52-week?

      LPCN's closing price is 0.06% higher than its 52-week low of $3.3 where as its distance from 52-week high of $16.15 is -0.74%.

      icon

      How many employees does LPCN have?

      Number of LPCN employees currently stands at 17.00. LPCN operates from 675 Arapeen Drive</br>Salt Lake City, UT 84108</br>US.

      icon

      Link for LPCN official website?

      Official Website of LPCN is: https://www.lipocine.com

      icon

      How do I contact LPCN?

      LPCN could be contacted at phone #801 994 7383 and can also be accessed through its website. LPCN operates from 675 Arapeen Drive</br>Salt Lake City, UT 84108</br>US.

      icon

      How many shares of LPCN are traded daily?

      LPCN stock volume for the day was 15435.00 shares. The average number of LPCN shares traded daily for last 3 months was 17.54 Thousands.

      icon

      What is the market cap of LPCN currently?

      The market value of LPCN currently stands at $20.65 Million with its latest stock price at $4.66 and 90.19 Million of its shares outstanding.